Table 1.

Subject demographics

Dose (mcg/kg)SubjectAgeGenderCancer typeCycles completedOff-study for
0.25175MRenal2Progression
0.25261MLung4Completed
0.25355MRenal4Progression
0.5438FLung4Progression
0.5574MRenal24Completed
0.5658FMelanoma2Progression
1.0771MSCCHN1Discontinueda
1.0869FLung4Completed
1.0961FMelanoma2Progression
2.01062MMelanoma1Adverse Event
2.01159MRenal2Progression
2.01277MRenal2Adverse event
2.01360MLung6Completed
2.01444MSCCHN2Progression
2.01553MRenal2Progression
3.01678FRenal4Progression
3.01775MSCCHN1Progression
3.01859FLung1Adverse Event
3.01961FLung2Progression
  • Abbreviation: completed, completed 4 cycles (or more) without disease progression; F, female; M, male.

  • aResponse assessment not performed; patient discontinued study participation.